While the Japanese market with its increasingly globally-minded pharma companies still dominates deal activities in the Asia-Pacific region, companies and research institutes in the emerging markets of South Korea, China and India reported almost as many deals as Australia during Q3 2009 to Q2 2010.
Features and benefits
* Gain insight into the number and scope of deals and alliances in Asia-Pacific, and key drivers and resistors.* Identify the most targeted pharmaceutical sectors in terms of deal activity, and which companies have shown the most interest in Asia-Pacific.* Identify the markets most frequently targeted through licensing and other deal types, and which have attracted the attention of Big Pharma.
Highlights
Over 300 licensing, market/distribution, research/discovery and other deal types involving APAC-based companies and research institutes were reported between Q3 2009 and Q2 2010. Most were licensing deals and market, promotion and distribution agreements, with the majority targeting territories within APAC.Japan signed twice as many deals as most other APAC nations, driven by its large pharmaceutical companies. Australia followed, with its strong research base and biotechnology industry, while South Korea outpaced larger rivals India and China due to a more developed economy and business environment which has attracted international partners.Research and development deals will increase as capabilities and capacity in APAC grow, with much of this activity driven by universities and research institutes. Greater flexibility in deal types and structures—including co-promotion agreements and option-based deals—is likely to continue to boost the activity seen in the region.
Your key questions answered
* What are the key drivers and resistors of licensing and other deal activity in the Asia-Pacific region?* How do trends in deal making differ between the emerging and developed markets in Asia-Pacific?* Which companies are most active in licensing and alliances in the Asia-Pacific region?
ABOUT DATAMONITOR HEALTHCARE 2
About the Healthcare Strategic Analysis Team 2
About the Healthcare Asia-Pacific Team 3
1. Executive Summary 4
Strategic scoping and focus 4
Key findings 5
Key definitions 6
Related reports 8
Upcoming related reports 8
2. Overview of the APAC pharmaceutical markets 11
Key findings 11
Developed healthcare and pharmaceutical markets 13
Emerging healthcare and pharmaceutical markets 25
3. Evolving trends in the licensing landscape 54
Key findings 54
Drivers and resistors of licensing and alliances in APAC 55
Big Pharma trends in APAC licensing and alliances 66
Future outlook for licensing deals and alliances in APAC 71
4. Overview of licensing and alliances in APAC 75
Key findings 75
Primary focus of deals in APAC 77
Licensing trends 81
Research and development deals 98
Marketing, promotion and distribution deals 108
Option agreements and joint ventures 121
5. Country-specific deals and trends 124
Key findings 124
Licensing and alliances in key APAC markets 125
Licensing and alliances in other developed APAC markets 134
Licensing and alliances in notable emerging APAC markets 140
Other APAC markets 145
6. Bibliography 147
Overview of the APAC pharmaceutical markets 147
Evolving trends in the licensing landscape 152
Overview of licensing and alliances in APAC 154
Country-specific deals and trends 155
APPENDIX 157
Methodology 157
Key definitions 158
Exchange rates 159
About Datamonitor 160
Datamonitor consulting 160
Disclaimer 162
Other selected research from the 'Business Development' category:
Partneringdesk Otsuka Pharmaceuticals Co and Company Deals Briefing
Late Stage Deals: Strategy, Structure and Payment Terms
Other selected research from the 'Marketing & Sales' category:
Co-promotion and Co-marketing Partnering Terms and Agreements in Pharma, Biotech and Diagnostics, 5th edition
Companion Diagnostics Partnering Terms & Agreements